KR20020012218A - 프로스타글란딘 e1 전달용 국소 조성물 - Google Patents
프로스타글란딘 e1 전달용 국소 조성물 Download PDFInfo
- Publication number
- KR20020012218A KR20020012218A KR1020017014474A KR20017014474A KR20020012218A KR 20020012218 A KR20020012218 A KR 20020012218A KR 1020017014474 A KR1020017014474 A KR 1020017014474A KR 20017014474 A KR20017014474 A KR 20017014474A KR 20020012218 A KR20020012218 A KR 20020012218A
- Authority
- KR
- South Korea
- Prior art keywords
- topical composition
- composition
- prostaglandin
- topical
- alkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 165
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title claims abstract description 60
- 230000000699 topical effect Effects 0.000 title claims description 56
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title description 3
- 229960000711 alprostadil Drugs 0.000 title description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title 1
- -1 polysaccharide lipid compounds Chemical class 0.000 claims abstract description 42
- 230000035515 penetration Effects 0.000 claims abstract description 35
- 150000002634 lipophilic molecules Chemical class 0.000 claims abstract description 21
- 239000003623 enhancer Substances 0.000 claims abstract description 20
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 15
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 13
- 230000002378 acidificating effect Effects 0.000 claims abstract description 7
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 5
- 201000001881 impotence Diseases 0.000 claims abstract description 5
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 claims description 18
- 229920002125 Sokalan® Polymers 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 15
- 239000007853 buffer solution Substances 0.000 claims description 13
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical group CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 150000003180 prostaglandins Chemical class 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229920000161 Locust bean gum Polymers 0.000 claims description 9
- 235000010420 locust bean gum Nutrition 0.000 claims description 9
- 239000000711 locust bean gum Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229920000926 Galactomannan Polymers 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 7
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical group O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- NCXUNZWLEYGQAH-UHFFFAOYSA-N 1-(dimethylamino)propan-2-ol Chemical group CC(O)CN(C)C NCXUNZWLEYGQAH-UHFFFAOYSA-N 0.000 claims description 3
- KTPHASGENPMMQK-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl dodecanoate Chemical group CCCCCCCCCCCC(=O)OC(C)CN(C)C KTPHASGENPMMQK-UHFFFAOYSA-N 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- KIPQYJOLEGBNHQ-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl tetradecanoate Chemical group CCCCCCCCCCCCCC(=O)OC(C)CN(C)C KIPQYJOLEGBNHQ-UHFFFAOYSA-N 0.000 claims description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000036332 sexual response Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims 1
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical group CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 150000002148 esters Chemical class 0.000 abstract description 12
- 239000000872 buffer Substances 0.000 abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract 1
- 229940126702 topical medication Drugs 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000270295 Serpentes Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 240000008886 Ceratonia siliqua Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000017367 Guainella Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 150000004862 dioxolanes Chemical class 0.000 description 2
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229950005134 polycarbophil Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- KCOPAESEGCGTKM-UHFFFAOYSA-N 1,3-oxazol-4-one Chemical compound O=C1COC=N1 KCOPAESEGCGTKM-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FGBGMOBXVFWPCI-UHFFFAOYSA-N ethyl dodecanoate;tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCC(=O)OCC FGBGMOBXVFWPCI-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229930187294 kinoin Natural products 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940107644 prostin vr Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
국소용 프로스타글란딘 E1조성물 성분(중량%) | A | B | C | D | E | F | G | |
파트 A | 전수화시킨 로커스트콩 검 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
물/완충액(pH 5.5) | 81 | 81 | 81 | 81 | 81 | 81 | 81 | |
수크로오스 스테아레이트 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
파트 B | 프로스타글란딘 E1 | 0.1 | 0.2 | 0.3 | 0.4 | 0.4 | 0.5 | 0.4 |
DDAIP | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |
에탄올 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | |
에틸 라우레이트 | 5 | 5 | 5 | 5 | 5 | 5 | - |
축적된 프로스타글란딘 E1침투력(㎍/㎠) | |||||||
시간 | A | B | C | D | E | F | G |
1 | 1.95 | 3.37 | 5.47 | 7.20 | 7.09 | 10.38 | 3.03 |
2 | 5.49 | 9.72 | 18.06 | 21.26 | 16.6 | 25.03 | 8.17 |
3 | 11.25 | 18.18 | 30.34 | 35.53 | 28.54 | 42.18 | 12.93 |
4 | 13.98 | 23.48 | 38.49 | 47.98 | 41.1 | 52.13 | 18.71 |
비교예 | |||
성분(중량%) | 비교예 조성물1 | 비교예 조성물2 | |
파트A | 전수화된 로커스트콩 검 | 3 | 3 |
물/완충액(pH 5.5) | 86 | 81 | |
수크로오스 스테아레이트 | 0.5 | 0.5 | |
파트 B | 프로스타글란딘 E1 | 0.4 | 0.4 |
에탄올 | 5 | 10 | |
에틸 라우레이트 | 5 | 5 |
비교예(축적된 프로스타글란딘 E1침투력(㎍/㎠) | ||
시간 | 비교예 조성물1 | 비교예 조성물2 |
1 | 2.64 | 1.55 |
2 | 4.46 | 3.69 |
3 | 6.59 | 6.63 |
4 | 9.67 | 11.05 |
Claims (33)
- 프로스타글란딘 E1;알킬-2-(N,N-이치환된 아미노)-알카노에이트, (N,N-이치환된)-알칸올 알카노에이트 및 이들의 혼합물로 이루어지는 군중의 한 성분인 피부 침투 증강제;폴리사카라이드 검 또는 폴리아크릴산 중합체;C1내지 C8의 지방족 알코올, C1내지 C8의 지방족 에스테르 및 이들의 혼합물로 이루어지는 군중의 한 성분인 친지질성 화합물; 및산성 완충 시스템을 포함하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 하기 화학식으로 표시되는 알킬-2-(N,N-이치환된 아미노)-알카노에이트인 것을 특징으로 하는 국소용 조성물:상기 식에서,n은 대략 4 내지 대략 18의 범위에 있는 값을 갖는 정수이고;R은 수소, C1내지 C7의 알킬, 벤질 및 페닐로 이루어진 군중의 한 성분이며;R1와 R2는 수소 및 C1내지 C7의 알킬로 이루어진 군중의 한 성분이고;R3와 R4는 수소, 메틸 및 에틸로 이루어진 군중의 한 성분이다.
- 제1항에 있어서, 침투 증강제가 C4내지 C18의 알킬-(N,N-이치환된 아미노)-아세테이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 도데실-(N,N-디메틸아미노)-아세테이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 도데실-2-(N,N-디메틸아미노)-프로피오네이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 하기 화학식으로 표시되는 (N,N-이치환된 아미노)-알칸올 알카노에이트인 것을 특징으로 하는 국소용 조성물:상기 식에서,n은 대략 5 내지 대략 18의 범위에 있는 값을 갖는 정수이고;y는 대략 0 내지 대략 5의 범위에 있는 값을 갖는 정수이며;R1, R2, R3, R4, R5, R6와 R7은 수소, C1내지 C8의 알킬 및 C1내지 C8의 아릴로 이루어지는 군중의 성분이고;R8은 수소, 히드록시, C1내지 C8의 알킬 및 C1내지 C8의 아릴로 이루어지는 군중의 한 성분이다.
- 제1항에 있어서, 침투 증강제가 C5내지 C18의 카르복실산 에스테르인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 1-(N,N-디메틸아미노)-2-프로판올 도데카노에이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 1-(N,N-디메틸아미노)-2-프로판올 미리스테이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 1-(N,N-디메틸아미노)-2-프로판올 올레이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 폴리사카라이드 검이 갈락토만난 검인 것을 특징으로 하는 국소용 조성물.
- 제11항에 있어서, 갈락토만난 검이 로커스트콩(locust bean) 검인 것을 특징으로 하는 국소용 조성물.
- 제11항에 있어서, 갈락토만난 검이 구아 검인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 에탄올인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 폴리올 지방족 알코올인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 이소프로필 미리스테이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 에틸 라우레이트인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 에탄올과 이소프로필 미리스테이트의 혼합물인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 친지질성 화합물이 에탄올과 에틸 라우레이트의 혼합물인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 산성 완충 시스템이 조성물에 대해 대략 3 내지 대략 7.4의 범위에 있는 완충된 pH 값을 제공할 수 있는 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 침투 증강제가 도데실-2-(N,N-디메틸아미노)-프로피오네이트이고, 폴리사카라이드 검이 로커스트콩 검이며, 친지질성 화합물이 에탄올과 에틸 라우레이트의 혼합물인 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 조성물의 전체 중량을 기준으로 해서, 0.5 내지 5중량%의 로커스트콩 검, 0.5 내지 25중량%의 도데실 2-(N,N-디메틸아미노)-프로피오네이트, 0.5 내지 80중량%의 에탄올 및 0.5 내지 80중량%의 이소프로필 미리스테이트를 함유하는 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 국소용 약제 투여형을 제조하기 위한 조성물의 전체 중량을기준으로 해서, 0.5 내지 5중량%의 로커스트콩 검, 0.5 내지 5중량%의 도데실 2-(N,N-디메틸아미노)-프로피오네이트, 0.5 내지 25중량%의 에탄올 및 0.5 내지 25중량%의 에틸 라우레이트를 함유하는 것을 특징으로 하는 국소용 조성물.
- 제1항에 있어서, 유화제를 더 함유하는 것을 특징으로 하는 국소용 조성물.
- 제24항에 있어서, 유화제가 수크로오스 에스테르인 것을 특징으로 하는 국소용 조성물.
- 제24항에 있어서, 유화제가 수크로오스 스테아레이트인 것을 특징으로 하는 국소용 조성물.
- 프로스타글란딘 E1;알킬-2-(N,N-이치환된 아미노)-알카노에이트, (N,N-이치환된)-알칸올 알카노에이트 및 이들의 혼합물로 이루어진 군중의 한 성분인 피부 침투 증강제;폴리아크릴산 중합체;C1내지 C8의 지방족 알코올, C8내지 C30의 지방족 에스테르 및 이들의 혼합물로 이루어진 군중의 한 성분인 친지질성 화합물; 및국소용 약제 투여형을 제조하기 위한 산성 완충 시스템을 포함하는 국소용프로스타글란딘 조성물.
- 제27항에 있어서, 폴리아크릴산 중합체는 카르보머인 것을 특징으로 하는 국소용 조성물.
- 경피적인 또는 경점막적으로 투여하는 것을 목적으로 하는 약제 조성물을 제조하기 위한 제1 내지 제28항 중 어느 한 항에 따른 국소용 조성물의 용도.
- 제29항에 있어서, 여성 성기능 장애 치료용인 것을 특징으로 하는 조성물의 용도.
- 제29항에 있어서, 말초 혈관질환 치료용인 것을 특징으로 하는 조성물의 용도.
- 제29항에 있어서, 남성 발기부전 치료용인 것을 특징으로 하는 조성물의 용도.
- 제29항에 있어서, 여성 성적반응 증강용인 것을 특징으로 하는 조성물의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/964,509 US6046244A (en) | 1997-11-05 | 1997-11-05 | Topical compositions for prostaglandin E1 delivery |
PCT/US1999/010596 WO2000069469A1 (en) | 1997-11-05 | 1999-05-13 | Topical compositions for prostaglandin e1 delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020012218A true KR20020012218A (ko) | 2002-02-15 |
KR100462442B1 KR100462442B1 (ko) | 2004-12-17 |
Family
ID=25508632
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007004907A KR100576986B1 (ko) | 1997-11-05 | 1998-11-05 | 프로스타글란딘 e₁ 운반용 국소 조성물 |
KR10-2001-7014474A KR100462442B1 (ko) | 1997-11-05 | 1999-05-13 | 국소용 프로스타글란딘 조성물을 제조하는 방법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007004907A KR100576986B1 (ko) | 1997-11-05 | 1998-11-05 | 프로스타글란딘 e₁ 운반용 국소 조성물 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6046244A (ko) |
EP (2) | EP1028708B1 (ko) |
JP (2) | JP4491560B2 (ko) |
KR (2) | KR100576986B1 (ko) |
CN (2) | CN1191060C (ko) |
AT (2) | ATE455535T1 (ko) |
AU (1) | AU757086B2 (ko) |
BR (2) | BR9813945A (ko) |
CA (2) | CA2309165A1 (ko) |
DE (2) | DE69841463D1 (ko) |
DK (2) | DK1028708T3 (ko) |
ES (2) | ES2338389T3 (ko) |
HK (2) | HK1034678A1 (ko) |
HU (1) | HU230300B1 (ko) |
IL (3) | IL135914A0 (ko) |
MX (1) | MXPA01011560A (ko) |
PT (1) | PT1178833E (ko) |
TR (2) | TR200002158T2 (ko) |
TW (1) | TW443933B (ko) |
WO (2) | WO1999022714A1 (ko) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
GR1003199B (el) * | 1998-08-14 | 1999-09-01 | Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες | |
US6825234B2 (en) * | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
EA008720B1 (ru) * | 1998-12-10 | 2007-06-29 | Нексмед (Холдингс), Инк. | Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20050004226A1 (en) * | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20070191320A1 (en) * | 1998-12-10 | 2007-08-16 | Nexmed Holdings, Inc. | Methods of treatment for female sexual arousal disorder |
WO2000051978A1 (en) | 1999-03-01 | 2000-09-08 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US6323241B1 (en) * | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
KR100402334B1 (ko) * | 2000-06-23 | 2003-10-22 | 환인제약 주식회사 | 알프로스타딜 외용제 |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
KR100373540B1 (ko) * | 2000-09-20 | 2003-02-25 | 최한곤 | 프로스타글란딘 e1용 요도좌제 조성물 |
KR100810404B1 (ko) * | 2001-12-18 | 2008-03-04 | 환인제약 주식회사 | 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물 |
US20050159485A1 (en) * | 2002-01-04 | 2005-07-21 | Jost-Price Edward R. | Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases |
HUP0402673A2 (hu) * | 2002-02-15 | 2005-04-28 | Nexmed (Holdings), Inc. | Erekciózavar kezelésére szolgáló prosztaglandin készítmény |
US20060100181A1 (en) * | 2002-05-03 | 2006-05-11 | Jost-Price Edward R | Combinations for the treatment of inflammatory skin disorders |
AU2003252040A1 (en) * | 2002-07-17 | 2004-02-02 | Liquidmetal Technologies | Method of making dense composites of bulk-solidifying amorphous alloys and articles thereof |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
JP4540667B2 (ja) * | 2003-03-21 | 2010-09-08 | ネクスメツド・ホールデイングス・インコーポレイテツド | 抗真菌性ネイルコート |
EP1605948A1 (en) * | 2003-03-21 | 2005-12-21 | Nexmed Holdings, Inc. | Prostaglandin compositions for the treatment of erectile dysfunction |
US20040241243A1 (en) * | 2003-03-21 | 2004-12-02 | Nexmed (Holdings) Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
JP2006522136A (ja) * | 2003-04-02 | 2006-09-28 | ネックスメド ホールディングス インコーポレイテッド | プロスタグランジン組成物および血管痙攣の治療のためのその使用 |
AU2012201048B2 (en) * | 2004-04-19 | 2013-06-06 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
CA2563678A1 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
EP2380579A1 (en) * | 2004-04-19 | 2011-10-26 | Strategic Science & Technologies, LLC | Beneficial effects of increasing local blood flow |
US20050276865A1 (en) * | 2004-05-20 | 2005-12-15 | Servet Buyuktimkin | Peroxide compounds for the prevention and treatment of sexual dysfunction in humans |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
RS52671B (en) | 2005-10-12 | 2013-06-28 | Unimed Pharmaceuticals Llc | IMPROVED TESTOSTERON GEL AND USE PROCEDURE |
US8358785B2 (en) * | 2006-05-30 | 2013-01-22 | Siemens Audiologische Technik Gmbh | Hearing system with wideband pulse transmitter |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
US7560489B2 (en) * | 2006-10-11 | 2009-07-14 | Nexmed Holdings, Inc. | Stabilized prostaglandin E composition |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
MX2011003568A (es) | 2008-10-03 | 2011-06-09 | Nexmed Holdings Inc | Composicion estabilizada para el tratamiento de psoriasis. |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
MX337166B (es) | 2009-06-24 | 2016-02-15 | Composicion topica que contiene ibuoprofeno. | |
WO2010151241A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
KR20130079382A (ko) * | 2010-05-04 | 2013-07-10 | 넥스메드 홀딩스 인코포레이티드 | 소분자 치료제의 조성물 |
KR20140016239A (ko) * | 2010-09-24 | 2014-02-07 | 넥스메드 홀딩스 인코포레이티드 | 협측을 통한 향상된 약물 전달 시스템 및 조성물 |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN105920603B (zh) | 2010-12-29 | 2022-02-11 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
JP2014510156A (ja) * | 2011-04-07 | 2014-04-24 | ネクスメッド ホールディングス,インコーポレイテッド | レイノー病を治療する方法および組成物 |
ITRM20120036A1 (it) * | 2012-02-02 | 2013-08-03 | Robert Davis Steigerwalt Jr | Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare. |
US20150320764A1 (en) * | 2014-05-09 | 2015-11-12 | Nexmed Holdings, Inc. | Treating female sexual arousal disorder and related symptoms |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5948409A (ja) * | 1982-09-10 | 1984-03-19 | Teikoku Seiyaku Kk | 矯正的歯牙移動促進剤 |
DK243084A (da) * | 1983-05-26 | 1984-11-27 | Takeda Chemical Industries Ltd | Perkutane farmaceutiske praeparater til udvortes brug |
GB8416638D0 (en) * | 1984-06-29 | 1984-08-01 | Beecham Group Plc | Topical treatment and composition |
US4732892A (en) * | 1985-07-12 | 1988-03-22 | American Home Products Corporation | L-α-amino acids as transdermal penetration enhancers |
US4771004A (en) * | 1986-08-29 | 1988-09-13 | Iprx, Inc. | Method for in vitro determination of transdermal absorption |
US4808414A (en) * | 1986-09-29 | 1989-02-28 | Nelson Research & Development Co. | Amide penetration enhancers for transdermal delivery of systemic agents |
US5219885A (en) * | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
US4865848A (en) * | 1987-02-26 | 1989-09-12 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
EP0302147A1 (en) * | 1987-08-03 | 1989-02-08 | The Procter & Gamble Company | Topical tanning compositions |
US4980378A (en) * | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
US5534260A (en) * | 1989-02-23 | 1996-07-09 | University Of Utah | Percutaneous drug delivery system |
US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
JP3202777B2 (ja) * | 1992-01-24 | 2001-08-27 | リンテック株式会社 | 経皮吸収促進剤及びテープ製剤 |
US5380760A (en) * | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
DK1473031T3 (da) * | 1993-12-13 | 2008-10-20 | Avanir Pharmaceuticals | Sucroseester - C20 til C28 alkoholformuleringer |
US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
-
1997
- 1997-11-05 US US08/964,509 patent/US6046244A/en not_active Expired - Lifetime
-
1998
- 1998-11-05 WO PCT/US1998/023576 patent/WO1999022714A1/en active IP Right Grant
- 1998-11-05 IL IL13591498A patent/IL135914A0/xx not_active IP Right Cessation
- 1998-11-05 CA CA002309165A patent/CA2309165A1/en not_active Abandoned
- 1998-11-05 DK DK98957603.8T patent/DK1028708T3/da active
- 1998-11-05 TR TR2000/02158T patent/TR200002158T2/xx unknown
- 1998-11-05 DE DE69841463T patent/DE69841463D1/de not_active Expired - Lifetime
- 1998-11-05 KR KR1020007004907A patent/KR100576986B1/ko not_active IP Right Cessation
- 1998-11-05 ES ES98957603T patent/ES2338389T3/es not_active Expired - Lifetime
- 1998-11-05 AT AT98957603T patent/ATE455535T1/de active
- 1998-11-05 EP EP98957603A patent/EP1028708B1/en not_active Expired - Lifetime
- 1998-11-05 CN CNB988129159A patent/CN1191060C/zh not_active Expired - Lifetime
- 1998-11-05 JP JP2000518648A patent/JP4491560B2/ja not_active Expired - Lifetime
- 1998-11-05 BR BR9813945-2A patent/BR9813945A/pt not_active Application Discontinuation
- 1998-12-07 TW TW087118421A patent/TW443933B/zh not_active IP Right Cessation
-
1999
- 1999-05-13 KR KR10-2001-7014474A patent/KR100462442B1/ko not_active IP Right Cessation
- 1999-05-13 AU AU39891/99A patent/AU757086B2/en not_active Expired
- 1999-05-13 PT PT99923024T patent/PT1178833E/pt unknown
- 1999-05-13 CA CA002373821A patent/CA2373821C/en not_active Expired - Lifetime
- 1999-05-13 CN CNB998167886A patent/CN1195523C/zh not_active Expired - Lifetime
- 1999-05-13 DE DE69919594T patent/DE69919594T2/de not_active Expired - Lifetime
- 1999-05-13 JP JP2000617929A patent/JP2002544240A/ja active Pending
- 1999-05-13 MX MXPA01011560A patent/MXPA01011560A/es active IP Right Grant
- 1999-05-13 IL IL14647099A patent/IL146470A0/xx unknown
- 1999-05-13 DK DK99923024T patent/DK1178833T3/da active
- 1999-05-13 ES ES99923024T patent/ES2224661T3/es not_active Expired - Lifetime
- 1999-05-13 AT AT99923024T patent/ATE273714T1/de active
- 1999-05-13 EP EP99923024A patent/EP1178833B1/en not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/010596 patent/WO2000069469A1/en active IP Right Grant
- 1999-05-13 HU HU0201145A patent/HU230300B1/hu unknown
- 1999-05-13 TR TR2002/00146T patent/TR200200146T2/xx unknown
- 1999-05-13 BR BR9917299-2A patent/BR9917299A/pt not_active Application Discontinuation
-
2001
- 2001-08-03 HK HK01105414A patent/HK1034678A1/xx not_active IP Right Cessation
- 2001-11-13 IL IL146470A patent/IL146470A/en not_active IP Right Cessation
-
2002
- 2002-08-13 HK HK02105901.5A patent/HK1044289B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100462442B1 (ko) | 국소용 프로스타글란딘 조성물을 제조하는 방법 | |
KR100614361B1 (ko) | 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법 | |
KR100621817B1 (ko) | 비스테로이드성 소염(nsai) 약물을 포함하는 국소 투여용 수성 약제학적 조성물 | |
EP1510213B1 (en) | Penetration enhancing and irritation reducing systems comprising testosterone | |
ZA200505321B (en) | Topical stabilized prostaglandin E compound dosage forms | |
KR20030060769A (ko) | 프로스타글란딘 e₁을 함유하는 국소 조성물 | |
KR20040033024A (ko) | 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법 | |
KR20040082431A (ko) | 발기기능장애를 치료하기 위한 프로스타글란딘 조성물 | |
KR20050119187A (ko) | 프로스타글란딘 조성물 및 이의 혈관연축 치료용 용도 | |
CA2442479C (en) | Topical compositions for prostaglandin e1 delivery | |
GB2236250A (en) | Ibuprofen solutions and topical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E801 | Decision on dismissal of amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121126 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20131125 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20141124 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20151124 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20161125 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180328 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20181206 Year of fee payment: 15 |
|
EXPY | Expiration of term |